The chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) is a G protein-coupled receptor that mediates the pro-inflammatory effects of prostaglandin D 2 (PGD 2 ) generated in allergic inflammation. The CRTH2 receptor shares greatest sequence similarity with chemoattractant receptors compared with prostanoid receptors. To investigate the structural determinants of CRTH2 ligand binding, we performed site-directed mutagenesis of putative mCRTH2 ligand-binding residues, and we evaluated mutant receptor ligand binding and functional properties. Substitution of alanine at each of three residues in the transmembrane (TM) helical domains (His-106, TM III; Lys-209, TM V; and Glu-268, TM VI) and one in extracellular loop II (Arg-178) decreased PGD 2 binding affinity, suggesting that these residues play a role in binding PGD 2 . In contrast, the H106A and E268A mutants bound indomethacin, a nonsteroidal anti-inflammatory drug, with an affinity similar to the wild-type receptor. HEK293 cells expressing the H106A, K209A, and E268A mutants displayed reduced inhibition of intracellular cAMP and chemotaxis in response to PGD 2 , whereas the H106A and E268A mutants had functional responses to indomethacin similar to the wild-type receptor. Binding of PGE 2 by the E268A mutant was enhanced compared with the wild-type receptor, suggesting that Glu-268 plays a role in determining prostanoid ligand selectivity. Replacement of Tyr-261 with phenylalanine did not affect PGD 2 binding but decreased the binding affinity for indomethacin. These results provided the first details of the ligand binding pocket of an eicosanoid-binding chemoattractant receptor.
Prostaglandin D 2 (PGD 2 )3 is the predominant prostanoid species produced by allergen-activated mast cells (1, 2) and has been implicated in the pathogenesis of allergic diseases such as allergic asthma and atopic dermatitis (1, 3). Increased production or exposure to PGD 2 leads to elevated Th2-type cytokines and eosinophilic inflammation in murine asthma models (4, 5). However, the molecular mechanism of PGD 2 action in the pathogenesis of allergic disease remains only partially characterized.PGD 2 exerts its effects through two G protein-coupled receptors (GPCRs), the D prostanoid receptor (DP) and the recently discovered chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). DP receptor signaling has been linked to NF-B activation (6) and may influence dendritic cell function leading to skewing of the T cell response toward a Th2 phenotype (7). Mice deficient in the DP receptor display reduced Th2-mediated airway inflammation in the ovalbumin-induced asthma model (8), suggesting that PGD 2 signaling through the DP receptor plays a pro-inflammatory role in settings of allergic inflammation. On the other hand, PGD 2 has been hypothesized to exert anti-inflammatory effects by inhibiting dendritic cell migration and T cell activation (9).The role of PGD 2 signaling through the CRTH2 receptor in allergic disease is less well established. In ...